WorldCat Identities

Juul, Anders

Overview
Works: 29 works in 34 publications in 2 languages and 141 library holdings
Genres: Drama  Internet videos 
Roles: Actor, Other, Author, Contributor, Editor
Classifications: R129.B777, 616.994
Publication Timeline
.
Most widely held works by Anders Juul
A horrible woman = En frygtelig kvinde( Visual )

4 editions published in 2019 in Danish and held by 93 WorldCat member libraries worldwide

When Rasmus meets Marie, he is certain that she is the love of his life. However, it doesn{u2019}t take long before it turns out she is possessive and manipulative, and cunningly dissects Rasmus to pieces. Winner of Best Actress (Amanda Collin) and nominated for Best Film at the **Bodil Awards**. Nominated for Best Film at the **Warsaw International Film Festival**
Growth Hormone in Adults by Anders Juul( )

1 edition published in 2010 in English and held by 6 WorldCat member libraries worldwide

Serum levels of insulin-like growth factor I and its binding proteins in health and disease : physiological, epidemiological and clinical aspects by Anders Juul( Book )

2 editions published in 2003 in Danish and English and held by 4 WorldCat member libraries worldwide

Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism by COST Action BM1105( )

2 editions published in 2017 in English and held by 3 WorldCat member libraries worldwide

GHD Diagnostics in Europe and the US: An Audit of National Guidelines and Practice by Gerhard Binder( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Prenatal exposure to antifungal medication may change anogenital distance in male offspring: a preliminary study by Djamilla Madelung Mogensen( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective by Paulo F Collett-Solberg( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter: a case report by Maria Rossing( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

Current models of care for disorders of sex development - results from an International survey of specialist centres by Andreas Kyriakou( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

A randomized controlled trial on a multicomponent intervention for overweight school-aged children - Copenhagen, Denmark by Nina Majlund Harder-Lauridsen( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

CSCW i praksis : Lotus Notes i et shipping-firma( Book )

1 edition published in 1997 in Danish and held by 2 WorldCat member libraries worldwide

Diagnosis, Genetics, and Therapy of Short Stature in Children A Growth Hormone Research Society International Perspective by Paulo F Collett-Solberg( )

1 edition published in 2019 in English and held by 1 WorldCat member library worldwide

The Growth Hormone Research Society (GRS) convened a Workshop in March 2019 to evaluate the diagnosis and therapy of short stature in children. Forty-six international experts participated at the invitation of GRS including clinicians, basic scientists, and representatives from regulatory agencies and the pharmaceutical industry. Following plenary presentations addressing the current diagnosis and therapy of short stature in children, breakout groups discussed questions produced in advance by the planning committee and reconvened to share the group reports. A writing team assembled one document that was subsequently discussed and revised by participants. Participants from regulatory agencies and pharmaceutical companies were not part of the writing process. Short stature is the most common reason for referral to the pediatric endocrinologist. History, physical examination, and auxology remain the most important methods for understanding the reasons for the short stature. While some long-standing topics of controversy continue to generate debate, including in whom, and how, to perform and interpret growth hormone stimulation tests, new research areas are changing the clinical landscape, such as the genetics of short stature, selection of patients for genetic testing, and interpretation of genetic tests in the clinical setting. What dose of growth hormone to start, how to adjust the dose, and how to identify and manage a suboptimal response are still topics to debate. Additional areas that are expected to transform the growth field include the development of long-acting growth hormone preparations and other new therapeutics and diagnostics that may increase adult height or aid in the diagnosis of growth hormone deficiency
Serum levels of insulin-like growth factor-1 in first trimester of diabetic pregnancy : relation to early growth delay by Jan FOG Pedersen( )

in English and held by 1 WorldCat member library worldwide

Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : Objective: Only a few genetic loci are known to be associated with male pubertal events. The ability of excreting testosterone (T) and other steroids in the urine depends on sulfation and glucuronidation. One of several essential glucuronidases is encoded by the UGT2B17 gene. In a preliminary report, we found that homozygous deletion of UGT2B17 in boys was associated with lower urinary excretion of T. We hypothesized that boys with a lower glucuronidation capacity may have altered androgen action and excretion affecting pubarche, as this represents a T-dependent event. Design, participants and measures: 668 healthy boys (cross-sectional) aged 6.1-21.9 years (COPENHAGEN puberty study conducted from 2005 to 2006) were included. 65 of the boys where followed longitudinally every 6 months. Participants were genotyped for UGT2B17 copy number variation (CNV). Clinical pubertal staging including orchidometry, anthropometry and serum reproductive hormone levels. Results: 59 of the 668 boys (8.8%) presented with a homozygous deletion of UGT2B17 (del/del). These boys experienced pubarche at a mean age of 12.73 years (12.00-13.46) vs 12.40 years (12.11-12.68) in boys heterozygous for deletion of UGT2B17 (del/ins) vs 12.06 years (11.79-12.33) in boys with the wild-type genotype (ins/ins) (P = 0.029, corrected for BMI z -score). The effect accounted for 0.34 years delay per allele (95% CI: 0.03-0.64). A comparable trend was observed for onset of testicular enlargement>3 mL but did not reach significance. Conclusion: CNV of UGT2B17 is a factor contributing to the timing of male pubarche
Growth Hormone Research Society perspective on biomarkers of GH action in children and adults( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : Objective: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults and in patients with acromegaly. Participants: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry. Evidence: Current literature was reviewed and expert opinion was utilized to establish the state of the art and identify current gaps and unmet needs. Consensus process: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process. Conclusions: The clinical endpoint in paediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH-deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of comorbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly, normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly
Research report. Comparing reference charts for cross-sectional and longitudinal data( )

in English and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.44 (from 0.24 for A horrible ... to 0.97 for Growth Hor ...)

Languages
English (18)

Danish (7)